Cargando…

Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic

Due to the increasing prevalence of nonalcoholic steatohepatitis (NASH) and its associated health burden, there is a high need to develop therapeutic strategies for patients with this disease. Unfortunately, its long and asymptomatic natural history, the uncertainties about disease progression, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filozof, Claudia, Chow, Shein‐Chung, Dimick‐Santos, Lara, Chen, Yeh‐Fong, Williams, Richard N., Goldstein, Barry J., Sanyal, Arun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721443/ https://www.ncbi.nlm.nih.gov/pubmed/29404480 http://dx.doi.org/10.1002/hep4.1079

Ejemplares similares

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway
por: Filozof, Claudia, et al.
Publicado: (2015)

Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program
por: Williams, RN, et al.
Publicado: (2016)

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
por: Shi, Yi-wen, et al.
Publicado: (2023)

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints
por: Alkhouri, Naim, et al.
Publicado: (2019)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis
por: Regev, Arie, et al.
Publicado: (2019)

Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance
por: Gill, Ryan M., et al.
Publicado: (2023)

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2022)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2023)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis
por: Seen, Tasur Kumar, et al.
Publicado: (2021)

Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients
por: Bahrami, Hossein, et al.
Publicado: (2003)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis
por: Luo, Yi, et al.
Publicado: (2018)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
por: Twiss, James, et al.
Publicado: (2023)

New clinical score to diagnose nonalcoholic steatohepatitis in obese patients
por: Pulzi, Fernanda BU, et al.
Publicado: (2011)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials
por: He, Lingling, et al.
Publicado: (2016)

coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
por: Clearfield, Elizabeth, et al.
Publicado: (2021)

NIS2+™, an effective blood-based test for the diagnosis of at-risk nonalcoholic steatohepatitis in adults 65 years and older
por: Sanyal, Arun J., et al.
Publicado: (2023)

Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome
por: Castillo-Castro, Carolina, et al.
Publicado: (2021)

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis
por: Sanyal, Arun, et al.
Publicado: (2023)

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
por: Estes, Chris, et al.
Publicado: (2017)

Treatment of an Adolescent Female With Nonalcoholic Steatohepatitis–Related Cirrhosis With Liraglutide
por: Yuen, Christina, et al.
Publicado: (2023)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bmv2tkf7qdentimr3komc12ufj